Literature DB >> 19467941

Anterior tarsectomy long-term results in adult pes cavus.

S Naudi1, G Dauplat, V Staquet, S Parent, N Mehdi, C Maynou.   

Abstract

PURPOSE OF THE STUDY: Anterior tarsectomy for pes cavus in adults is designed to relieve pain and correct the deformity. The present study reports radiological and clinical results with anterior tarsectomy in 39 cases of pes cavus.
MATERIAL AND METHODS: The study concerned 39 cavus feet in 33 patients (22 males, 11 females; mean age: 31 years, range 16-49 years). Clinical outcome was assessed in terms of pain, function and motion, using the AOFAS classification. Radiological assessment (anteroposterior and lateral stress X-ray, views with Méary superficial wire-marking) measured the Djian angle, talometatarsal alignment, talar slope, calcaneal slope, calcaneal valgus, and osteoarthritis stage in adjacent joints.
RESULTS: Mean follow-up was 9.8 years (range, 1-25). Mean AOFAS score at follow-up was 69.2/100 points (range, 14-100). Pain decreased considerably in 75% of cases, and 68% of patients recovered normal activity. The foot was aligned correctly in 67% of cases. At last follow-up, pes cavus remained undercorrected in 80% of feet, but mean Djian angle had improved from 100 degrees to 111.3 degrees. Calcaneal valgus improved from 30.8 degrees to 24.8 degrees and the podoscopic footprint was normal in 51% of feet. In 74% of feet, adjacent joints presented progressive osteoarthritic degeneration. Subjectively, 70% of patients were very satisfied or satisfied with minor reservations. Objective outcome was excellent or good in 66% of feet. DISCUSSION AND
CONCLUSION: Outcome in terms of function, motion, complications and satisfaction was good, although pain relief results were poor. Anterior tarsectomy is able to correct initial pes cavus deformity and compensate anomalies of the hindfoot, but its correction capacity is limited, and its efficacy in case of clawfoot is poor. Anterior tarsectomy spares the adjacent Chopart complex and Lisfranc joints while inducing hypermobility, and leads to arthritis in 74% of cases. Better results are obtained in cases of reestablishment of the Méary-Tomeno line and of hindfoot valgus, as well as in cases of correction of equinus and clawfoot deformities. Worse results are observed in case of neurological evolutive disease or insufficient correction of the preceding deformities. LEVEL OF EVIDENCE: Level IV. Therapeutic Study. 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19467941     DOI: 10.1016/j.otsr.2009.03.013

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  5 in total

1.  Foot Type Biomechanics Part 2: are structure and anthropometrics related to function?

Authors:  Rajshree Mootanah; Jinsup Song; Mark W Lenhoff; Jocelyn F Hafer; Sherry I Backus; David Gagnon; Jonathan T Deland; Howard J Hillstrom
Journal:  Gait Posture       Date:  2012-10-26       Impact factor: 2.840

2.  Foot type biomechanics part 1: structure and function of the asymptomatic foot.

Authors:  Howard J Hillstrom; Jinsup Song; Andrew P Kraszewski; Jocelyn F Hafer; Rajshree Mootanah; Alyssa B Dufour; Betty Shingpui Chow; Jonathan T Deland
Journal:  Gait Posture       Date:  2012-10-26       Impact factor: 2.840

3.  The adult cavus foot.

Authors:  Carlos Maynou; Christophe Szymanski; Alexis Thiounn
Journal:  EFORT Open Rev       Date:  2017-05-11

4.  Is the Planus Foot Type Associated With First Ray Hypermobility?

Authors:  Oliver J Morgan; Rajshree Hillstrom; Robert Turner; Jonathan Day; Ibadet Thaqi; Kristin Caolo; Scott Ellis; Jonathan T Deland; Howard J Hillstrom
Journal:  Foot Ankle Orthop       Date:  2022-03-04

5.  A prospective study of midfoot osteotomy combined with adjacent joint sparing internal fixation in treatment of rigid pes cavus deformity.

Authors:  You Zhou; Binghua Zhou; Junpeng Liu; Xiaokang Tan; Xu Tao; Wan Chen; Kanglai Tang
Journal:  J Orthop Surg Res       Date:  2014-06-05       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.